Compare General Motors Company (GM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Twist Bioscience Corp — how do they compare? General Motors Company trades at $88.78 (market cap $78.40B), while Twist Bioscience Corp trades at $122.56 (market cap $7.72B). The key difference: General Motors Company is far larger — about 10.2× Twist Bioscience Corp's market cap, and General Motors Company pays a 0.81% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| GM | TWST | |
|---|---|---|
Market Cap | $78.40B | $7.72B |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $124.88 |
52-Week Low | $54.16 | $24.16 |
Enterprise Value | $181.38B | $7.65B |
Dividend Yield | 0.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $87.96, up 0.43% with a bullish technical signal and strong analyst support. The company shows robust cash flow generation ($26.87B operating cash flow in 2025) and has beaten earnings estimates for three consecutive quarters. Recent developments include a $4.5B parts supply deal and a renewed 20-year joint venture in China, positioning GM for supply chain stability and international growth.
GM presents a compelling investment case with 65% analyst buy ratings and a $108.82 consensus price target offering 24% upside. However, declining profit margins (1.05% net margin in 2025) and rising debt levels (46.79% debt-to-asset ratio) warrant caution. The stock's valuation appears reasonable with P/S of 0.45 and P/B of 1.26, but investors should monitor execution on EV strategy transitions and macroeconomic pressures on auto demand.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
